Sign in
Taking people in New ZealandPhase 1

First study of SRP-1005 in people with Huntington's disease

Tests the new drug SRP-1005 against a placebo in people with Huntington's disease.

Key facts

Who runs it
Sarepta Therapeutics, Inc.
Where
Christchurch, New ZealandSee the siteAlso in 4 other countries, 7 sites
Trial code
Registry title
A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
Status
Recruiting
Phase
Phase 1
People taking part
32 people, planned
Started
12 May 2026
Expected to end
30 Nov 2027
Type of study
Interventional, 4 groups
Treatments tested
  • SRP-1005
  • Placebo
Record updated
16 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Huntington's disease confirmed by a gene test, at an early to mild stage of the illness.

Age
21 Years to 70 Years
Sex
All sexes can join.
Disease stage
HD Integrated Staging System (HD-ISS) Stage 2 or Mild Stage 3.
Earlier treatment
People who recently used investigational agents or HTT-lowering therapies cannot join.
Biomarker or test result
Gene test confirms huntingtin (HTT) cytosine-adenine-guanine repeat length ≥40.

Main reasons for not taking part

  • A condition that makes lumbar puncture or MRI unsafe or not possible
  • Other significant neurological or systemic illnesses
  • Current, chronic or active HIV, hepatitis B/C
  • Uncontrolled psychiatric illness or substance use disorders
  • Pregnancy or lactation

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Genetically confirmed diagnosis of huntingtin (HTT) cytosine-adenine-guanine repeat length ≥40
  • Participant has HD Integrated Staging System (HD-ISS) Stage 2 or Mild Stage 3. At screening, the participant must be classified with the Enroll-HD HD-ISS Modified Calculator as either Stage 2 or Mild Stage 3
  • Participants who are of childbearing potential, or with partners of childbearing potential, who are sexually active must agree to use a highly effective method of contraception throughout study participation, and for at least 90 days following the end of study

Who cannot take part

  • Recent use of investigational agents or HTT-lowering therapies
  • Any condition that would compromise the safety or feasibility of lumbar puncture or magnetic resonance imaging (MRI)
  • Presence of other significant neurological or systemic illnesses
  • Current, chronic or active human immunodeficiency virus, hepatitis B/C
  • Uncontrolled psychiatric illness or substance use disorders
  • Pregnancy or lactation; Note: Other inclusion/exclusion criteria apply

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 21 and 70 years old?

This trial is currently available in New Zealand.

Also in 4 other countries, 7 sites

  • New Zealand Brain Research InstituteChristchurch, New ZealandContact: Timothy Anderson, MD, FRACP (principal investigator)Taking people

About the trial

What the trial wants to find out

This is a first-in-human, multi-center trial studying the effects of SRP-1005 in participants with Huntington's disease (HD).

The 4 groups in the trial

  • Cohort 1: SRP-1005 Dose 1Treatment being tested

    Participants will receive SRP-1005 or placebo.

    Treatment: SRP-1005 and Placebo

  • Cohort 2: SRP-1005 Dose 2Treatment being tested

    Participants will receive SRP-1005 or placebo.

    Treatment: SRP-1005 and Placebo

  • Cohort 3: SRP-1005 Dose 3Treatment being tested

    Participants will receive SRP-1005 or placebo.

    Treatment: SRP-1005 and Placebo

  • Cohort 4: SRP-1005 Dose 4Treatment being tested

    Participants will receive SRP-1005 or placebo.

    Treatment: SRP-1005 and Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Effect of SRP-1005 in Subjects With Huntington's Disease (INSIGHTT)
Plain-language title
First study of SRP-1005 in people with Huntington's diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Criteria questions
Built from NCT07536061, who can take part
Record updated
16 November 2026